Acetylcysteine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Acetylcysteine" in English language version.

refsWebsite

Global rank English rank

86nih.gov

4^th place

58doi.org

2^nd place

19semanticscholar.org

11^th place

8^th place

13web.archive.org

1^st place

5worldcat.org

5^th place

5handle.net

102^nd place

76^th place

4books.google.com

3^rd place

4fda.gov

447^th place

338^th place

3tga.gov.au

3,984^th place

2,622^nd place

3naturalproductsinsider.com

low place

2medscape.com

719^th place

636^th place

2harvard.edu

18^th place

17^th place

1healthdirect.gov.au

low place

1medicines.org.uk

3,823^rd place

2,387^th place

1drugs.com

399^th place

333^rd place

1sigmaaldrich.com

924^th place

2,352^nd place

1umm.edu

9,624^th place

low place

1patents.google.com

1,182^nd place

725^th place

1espacenet.com

800^th place

676^th place

1heartofengland.nhs.uk

low place

1archives-ouvertes.fr

1,031^st place

879^th place

1clinicaltrials.gov

5,225^th place

4,062^nd place

archives-ouvertes.fr

hal.archives-ouvertes.fr

Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, et al. (February 2010). "N-Acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus" (PDF). Biochemical Pharmacology. 79 (3): 413–420. doi:10.1016/j.bcp.2009.08.025. PMID 19732754.

books.google.com

Stockley RA (2008). Chronic Obstructive Pulmonary Disease a Practical Guide to Management. Chichester: John Wiley & Sons. p. 750. ISBN 9780470755280. Archived from the original on 8 September 2017.
Talbott SM (2012). A Guide to Understanding Dietary Supplements. Routledge. p. 469. ISBN 9781136805707. Archived from the original on 8 September 2017.
Fischer J, Ganellin CR (2006). Analogue-Based Drug Discovery. Weinheim: Wiley-VCH. p. 544. ISBN 9783527607495. Archived from the original on 8 September 2017.
Baker E (2014). "Acetylcysteine". Top 100 Drugs: Clinical pharmacology and practical prescribing. Elsevier Health Sciences. ISBN 9780702055157. Archived from the original on 8 September 2017.

clinicaltrials.gov

Clinical trial number NCT02541422 for "Use of NAC in Alleviation of Hangover Symptoms – Study Results" at ClinicalTrials.gov

doi.org

Sadowska AM, Verbraecken J, Darquennes K, De Backer WA (December 2006). "Role of N-acetylcysteine in the management of COPD". International Journal of Chronic Obstructive Pulmonary Disease. 1 (4): 425–434. doi:10.2147/copd.2006.1.4.425. ISSN 1176-9106. PMC 2707813. PMID 18044098.
Bin P, Huang R, Zhou X (2017). "Oxidation Resistance of the Sulfur Amino Acids: Methionine and Cysteine". BioMed Research International. 2017: 9584932. doi:10.1155/2017/9584932. PMC 5763110. PMID 29445748.
Lee BC, Dikiy A, Kim HY, Gladyshev VN (2009). "Functions and evolution of selenoprotein methionine sulfoxide reductases". Biochimica et Biophysica Acta (BBA) - General Subjects. 1790 (11): 1471–1477. doi:10.1016/j.bbagen.2009.04.014. PMC 3062201. PMID 19406207.
Green JL, Heard KJ, Reynolds KM, Albert D (May 2013). "Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis". The Western Journal of Emergency Medicine. 14 (3): 218–226. doi:10.5811/westjem.2012.4.6885. PMC 3656701. PMID 23687539.
Borgström L, Kågedal B, Paulsen O (1986). "Pharmacokinetics of N-acetylcysteine in man". European Journal of Clinical Pharmacology. 31 (2): 217–222. doi:10.1007/bf00606662. PMID 3803419. S2CID 41004554.
Dilger RN, Baker DH (July 2007). "Oral N-acetyl-L-cysteine is a safe and effective precursor of cysteine". Journal of Animal Science. 85 (7): 1712–1718. doi:10.2527/jas.2006-835. PMID 17371789.
Kanter MZ (October 2006). "Comparison of oral and i.v. acetylcysteine in the treatment of acetaminophen poisoning". American Journal of Health-System Pharmacy. 63 (19): 1821–1827. doi:10.2146/ajhp060050. PMID 16990628. S2CID 9209528.
Dawson AH, Henry DA, McEwen J (March 1989). "Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning". The Medical Journal of Australia. 150 (6): 329–331. doi:10.5694/j.1326-5377.1989.tb136496.x. PMID 2716644. S2CID 40296724.
Bailey B, McGuigan MA (June 1998). "Management of anaphylactoid reactions to intravenous N-acetylcysteine". Annals of Emergency Medicine. 31 (6): 710–715. doi:10.1016/S0196-0644(98)70229-X. PMID 9624310.
Schmidt LE, Dalhoff K (January 2001). "Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning". British Journal of Clinical Pharmacology. 51 (1): 87–91. doi:10.1046/j.1365-2125.2001.01305.x. PMC 2014432. PMID 11167669.
Lynch RM, Robertson R (January 2004). "Anaphylactoid reactions to intravenous N-acetylcysteine: a prospective case controlled study". Accident and Emergency Nursing. 12 (1): 10–15. doi:10.1016/j.aaen.2003.07.001. PMID 14700565.
Tam J, Nash EF, Ratjen F, Tullis E, Stephenson A (12 July 2013). "Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis" (PDF). The Cochrane Database of Systematic Reviews. 2013 (7): CD007168. doi:10.1002/14651858.CD007168.pub3. PMC 8078644. PMID 23852992. Archived from the original (PDF) on 27 March 2022. Retrieved 16 May 2018.
Grandjean EM, Berthet P, Ruffmann R, Leuenberger P (February 2000). "Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials". Clinical Therapeutics. 22 (2): 209–21. doi:10.1016/S0149-2918(00)88479-9. PMID 10743980.
Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR (August 2000). "The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review". The European Respiratory Journal. 16 (2): 253–262. doi:10.1034/j.1399-3003.2000.16b12.x. PMID 10968500.
Poole PJ, Black PN (May 2001). "Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review". BMJ. 322 (7297): 1271–1274. doi:10.1136/bmj.322.7297.1271. PMC 31920. PMID 11375228.
Garrett CE, Prasad K (2004). "The Art of Meeting Palladium Specifications in Active Pharmaceutical Ingredients Produced by Pd-Catalyzed Reactions". Advanced Synthesis & Catalysis. 346 (8): 889–900. doi:10.1002/adsc.200404071. S2CID 94929244.
Buijtels PC, Petit PL (July 2005). "Comparison of NaOH–N-acetyl cysteine and sulfuric acid decontamination methods for recovery of mycobacteria from clinical specimens". Journal of Microbiological Methods. 62 (1): 83–88. doi:10.1016/j.mimet.2005.01.010. PMID 15823396.
Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, et al. (February 2010). "N-Acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus" (PDF). Biochemical Pharmacology. 79 (3): 413–420. doi:10.1016/j.bcp.2009.08.025. PMID 19732754.
Aslam S, Darouiche RO (September 2011). "Role of antibiofilm-antimicrobial agents in controlling device-related infections". The International Journal of Artificial Organs. 34 (9): 752–758. doi:10.5301/ijao.5000024. PMC 3251652. PMID 22094553.
Palmer LA, Doctor A, Chhabra P, Sheram ML, Laubach VE, Karlinsey MZ, et al. (September 2007). "S-Nitrosothiols signal hypoxia-mimetic vascular pathology". The Journal of Clinical Investigation. 117 (9): 2592–2601. doi:10.1172/JCI29444. PMC 1952618. PMID 17786245.
Hildebrandt W, Alexander S, Bärtsch P, Dröge W (March 2002). "Effect of N-acetyl-cysteine on the hypoxic ventilatory response and erythropoietin production: linkage between plasma thiol redox state and O₂ chemosensitivity". Blood. 99 (5): 1552–5. doi:10.1182/blood.V99.5.1552. PMID 11861267. S2CID 24375953.
Wang AL, Wang JP, Wang H, Chen YH, Zhao L, Wang LS, et al. (March 2006). "A dual effect of N-acetylcysteine on acute ethanol-induced liver damage in mice". Hepatology Research. 34 (3): 199–206. doi:10.1016/j.hepres.2005.12.005. PMID 16439183.
Steullet P, Neijt HC, Cuénod M, Do KQ (2006). "Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia". Neuroscience. 137 (3): 807–819. doi:10.1016/j.neuroscience.2005.10.014. ISSN 0306-4522. PMID 16330153. S2CID 1417873.
Varga V, Jenei Z, Janáky R, Saransaari P, Oja SS (1997). "Glutathione Is an Endogenous Ligand of Rat Brain N-Methyl-D-Aspartate (NMDA) and 2-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionate (AMPA) Receptors". Neurochemical Research. 22 (9): 1165–1171. doi:10.1023/A:1027377605054. ISSN 0364-3190. PMID 9251108. S2CID 24024090.
Oja SS (2000). "Modulation of glutamate receptor functions by glutathione". Neurochemistry International. 37 (2–3): 299–306. doi:10.1016/S0197-0186(00)00031-0. ISSN 0197-0186. PMID 10812215. S2CID 44380765.
Berk M, Malhi GS, Gray LJ, Dean OM (March 2013). "The promise of N-acetylcysteine in neuropsychiatry". Trends in Pharmacological Sciences. 34 (3): 167–177. doi:10.1016/j.tips.2013.01.001. PMID 23369637.
Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, et al. (August 2008). "Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients". Neuropsychopharmacology. 33 (9): 2187–2199. doi:10.1038/sj.npp.1301624. hdl:10536/DRO/DU:30071388. PMID 18004285.
Dodd S, Dean O, Copolov DL, Malhi GS, Berk M (December 2008). "N-Acetylcysteine for antioxidant therapy: pharmacology and clinical utility". Expert Opinion on Biological Therapy. 8 (12): 1955–1962. doi:10.1517/14728220802517901. PMID 18990082. S2CID 74736842.
Kupchik YM, Moussawi K, Tang XC, Wang X, Kalivas BC, Kolokithas R, et al. (June 2012). "The effect of N-acetylcysteine in the nucleus accumbens on neurotransmission and relapse to cocaine". Biological Psychiatry. 71 (11): 978–986. doi:10.1016/j.biopsych.2011.10.024. PMC 3340445. PMID 22137594.
Dean O, Giorlando F, Berk M (March 2011). "N-Acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action". Journal of Psychiatry & Neuroscience. 36 (2): 78–86. doi:10.1503/jpn.100057. PMC 3044191. PMID 21118657.
Head SI (29 October 2017). "Antioxidant therapy in a mouse model of Duchenne muscular dystrophy: some promising results but with a weighty caveat". The Journal of Physiology. 595 (23): 7015. doi:10.1113/jp275232. ISSN 0022-3751. PMC 5709324. PMID 29034480.
Gu F, Chauhan V, Chauhan A (January 2015). "Glutathione redox imbalance in brain disorders". Current Opinion in Clinical Nutrition and Metabolic Care. 18 (1): 89–95. doi:10.1097/MCO.0000000000000134. PMID 25405315. S2CID 25333289.
Bavarsad Shahripour R, Harrigan MR, Alexandrov AV (March 2014). "N-Acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities". Brain and Behavior. 4 (2): 108–122. doi:10.1002/brb3.208. PMC 3967529. PMID 24683506.
Bachert C, Hörmann K, Mösges R, Rasp G, Riechelmann H, Müller R, et al. (March 2003). "An update on the diagnosis and treatment of sinusitis and nasal polyposis". Allergy. 58 (3): 176–191. doi:10.1034/j.1398-9995.2003.02172.x. PMID 12653791. S2CID 35319457.
Aitio ML (January 2006). "N-Acetylcysteine – passe-partout or much ado about nothing?". British Journal of Clinical Pharmacology. 61 (1): 5–15. doi:10.1111/j.1365-2125.2005.02523.x. PMC 1884975. PMID 16390346.
Williamson J, Doig WM, Forrester JV, Tham MH, Wilson T, Whaley K, et al. (September 1974). "Management of the dry eye in Sjogren's syndrome". The British Journal of Ophthalmology. 58 (9): 798–805. doi:10.1136/bjo.58.9.798. PMC 1215027. PMID 4433493.
Lindblad AC, Rosenhall U, Olofsson A, Hagerman B (November–December 2011). "The efficacy of N-acetylcysteine to protect the human cochlea from subclinical hearing loss caused by impulse noise: a controlled trial". Noise & Health. 13 (55): 392–401. doi:10.4103/1463-1741.90293. PMID 22122955.
Edwards MJ, Hargreaves IP, Heales SJ, Jones SJ, Ramachandran V, Bhatia KP, et al. (November 2002). "N-acetylcysteine and Unverricht-Lundborg disease: variable response and possible side effects". Neurology. 59 (9): 1447–1449. doi:10.1212/wnl.59.9.1447. PMID 12427904.
McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM (2014). "Potential role of N-acetylcysteine in the management of substance use disorders". CNS Drugs. 28 (2): 95–106. doi:10.1007/s40263-014-0142-x. PMC 4009342. PMID 24442756.
Coppersmith V, Hudgins S, Stoltzfus J, Stankewicz H (June 2021). "The use of N-acetylcysteine in the prevention of hangover: a randomized trial". Scientific Reports. 11 (1): 13397. Bibcode:2021NatSR..1113397C. doi:10.1038/s41598-021-92676-0. PMC 8238992. PMID 34183702. S2CID 235673455.
De Flora S, Grassi C, Carati L (1 July 1997). "Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment". European Respiratory Journal. 10 (7): 1535–1541. doi:10.1183/09031936.97.10071535. PMID 9230243.
Ryu CM, Shin JH, Yu HY, Ju H, Kim S, Lim J, et al. (May 2019). "N-acetylcysteine prevents bladder tissue fibrosis in a lipopolysaccharide-induced cystitis rat model". Scientific Reports. 9 (1): 8134. Bibcode:2019NatSR...9.8134R. doi:10.1038/s41598-019-44631-3. PMC 6544636. PMID 31148586.
Pistolesi V, Regolisti G, Morabito S, Gandolfini I, Corrado S, Piotti G, et al. (December 2018). "Contrast medium induced acute kidney injury: a narrative review". Journal of Nephrology. 31 (6): 797–812. doi:10.1007/s40620-018-0498-y. PMID 29802583. S2CID 44128861.
Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, et al. (September 2021). "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research. 143: 230–238. doi:10.1016/j.jpsychires.2021.09.018. PMID 34509090. S2CID 237485915.
Carollo M, Carollo N, Montan G (February 2024). "The promise of N-acetylcysteine in the treatment of obsessive-compulsive disorder". CNS Neuroscience & Therapeutics. 30 (2): e14653. doi:10.1111/cns.14653. PMC 10883097. PMID 38385640.
Slattery J, Kumar N, Delhey L, Berk M, Dean O, Spielholz C, et al. (August 2015). "Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review". Neuroscience and Biobehavioral Reviews. 55: 294–321. doi:10.1016/j.neubiorev.2015.04.015. PMID 25957927.
Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, et al. (June 2014). "The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial". The Journal of Clinical Psychiatry. 75 (6): 628–636. doi:10.4088/JCP.13m08454. PMID 25004186.
Oliver G, Dean O, Camfield D, Blair-West S, Ng C, Berk M, et al. (April 2015). "N-Acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review". Clinical Psychopharmacology and Neuroscience. 13 (1): 12–24. doi:10.9758/cpn.2015.13.1.12. PMC 4423164. PMID 25912534.
Samuni Y, Goldstein S, Dean OM, Berk M (August 2013). "The chemistry and biological activities of N-acetylcysteine". Biochimica et Biophysica Acta (BBA) - General Subjects. 1830 (8): 4117–4129. doi:10.1016/j.bbagen.2013.04.016. hdl:11343/43874. PMID 23618697. S2CID 2567773.
Minarini A, Ferrari S, Galletti M, Giambalvo N, Perrone D, Rioli G, et al. (2 November 2016). "N-Acetylcysteine in the treatment of psychiatric disorders: current status and future prospects". Expert Opinion on Drug Metabolism & Toxicology. 13 (3): 279–292. doi:10.1080/17425255.2017.1251580. hdl:11380/1116466. PMID 27766914. S2CID 20873065.
Hwang AS, Campbell EH, Sartori-Valinotti JC (July 2022). "Evidence of N-acetylcysteine efficacy for skin picking disorder: A retrospective cohort study". Journal of the American Academy of Dermatology. 87 (1): 148–150. doi:10.1016/j.jaad.2021.06.874. PMID 34224772. S2CID 235746237.
Popova L, Mancuso J (2022). "Dramatic Improvement of Trichotillomania with 6 Months of Treatment With N-Acetylcysteine". Global Pediatric Health. 9: 2333794X221086576. doi:10.1177/2333794X221086576. PMC 9133858. PMID 35647220.
Nery FG, Li W, DelBello MP, Welge JA (November 2021). "N-acetylcysteine as an adjunctive treatment for bipolar depression: A systematic review and meta-analysis of randomized controlled trials". Bipolar Disorders. 23 (7): 707–714. doi:10.1111/bdi.13039. PMID 33354859. S2CID 229692736.
Wong KK, Lee SW, Kua KP (2021). "N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence". Journal of Inflammation Research. 14: 2993–3013. doi:10.2147/JIR.S306849. PMC 8274825. PMID 34262324.
Assimakopoulos SF, Aretha D, Komninos D, Dimitropoulou D, Lagadinou M, Leonidou L, et al. (2021). "N-Acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study". Infectious Diseases (London, England). 53 (11): 847–854. doi:10.1080/23744235.2021.1945675. PMID 34182881. S2CID 235673520.
Kapur A, Sharma M, Sageena G (2022). "Therapeutic potential of N-acetyl cysteine during COVID-19 epoch". World Journal of Virology. 11 (2): 104–106. doi:10.5501/wjv.v11.i2.104. PMC 8966593. PMID 35433335.
Fesharaki-Zadeh A, Lowe N, Arnstien A (2022). "Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in "Long-COVID19"". Neuroimmunology Reports. 3 (3): 100154. doi:10.1016/j.nerep.2022.100154.
Kumar P, Osahon O, Vides DB, Hanania N, Minard CG, Sekhar RV (December 2021). "Severe Glutathione Deficiency, Oxidative Stress and Oxidant Damage in Adults Hospitalized with COVID-19: Implications for GlyNAC (Glycine and N-Acetylcysteine) Supplementation". Antioxidants. 11 (1): 50. doi:10.3390/antiox11010050. PMC 8773164. PMID 35052554.

drugs.com

"Acetylcysteine". The American Society of Health-System Pharmacists. Archived from the original on 23 September 2015. Retrieved 22 August 2015.

espacenet.com

worldwide.espacenet.com

US patent 3091569, Aaron Leonard Sheffner, "Mucolytic-N-acylated sulfhydryl compositions and process for treating animal mucus", published 28 May 1963, issued 28 May 1963, assigned to Mead Johnson & Co

fda.gov

"Warning Letter". benjaminmcevoy.com. U.S. Food and Drug Administration.
"FDA Sends Warning Letters to Seven Companies Illegally Selling Hangover Products".
"FDA Releases Draft Guidance on Enforcement Discretion for Certain NAC Products".

accessdata.fda.gov

"Acetadote Package Insert" (PDF). FDA. Archived (PDF) from the original on 25 August 2013. Retrieved 19 April 2014.

handle.net

hdl.handle.net

World Health Organization Model List of Essential Medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, et al. (August 2008). "Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients". Neuropsychopharmacology. 33 (9): 2187–2199. doi:10.1038/sj.npp.1301624. hdl:10536/DRO/DU:30071388. PMID 18004285.
Samuni Y, Goldstein S, Dean OM, Berk M (August 2013). "The chemistry and biological activities of N-acetylcysteine". Biochimica et Biophysica Acta (BBA) - General Subjects. 1830 (8): 4117–4129. doi:10.1016/j.bbagen.2013.04.016. hdl:11343/43874. PMID 23618697. S2CID 2567773.
Minarini A, Ferrari S, Galletti M, Giambalvo N, Perrone D, Rioli G, et al. (2 November 2016). "N-Acetylcysteine in the treatment of psychiatric disorders: current status and future prospects". Expert Opinion on Drug Metabolism & Toxicology. 13 (3): 279–292. doi:10.1080/17425255.2017.1251580. hdl:11380/1116466. PMID 27766914. S2CID 20873065.

harvard.edu

ui.adsabs.harvard.edu

Coppersmith V, Hudgins S, Stoltzfus J, Stankewicz H (June 2021). "The use of N-acetylcysteine in the prevention of hangover: a randomized trial". Scientific Reports. 11 (1): 13397. Bibcode:2021NatSR..1113397C. doi:10.1038/s41598-021-92676-0. PMC 8238992. PMID 34183702. S2CID 235673455.
Ryu CM, Shin JH, Yu HY, Ju H, Kim S, Lim J, et al. (May 2019). "N-acetylcysteine prevents bladder tissue fibrosis in a lipopolysaccharide-induced cystitis rat model". Scientific Reports. 9 (1): 8134. Bibcode:2019NatSR...9.8134R. doi:10.1038/s41598-019-44631-3. PMC 6544636. PMID 31148586.

healthdirect.gov.au

"Acetylcysteine (Omegapharm)". Healthdirect Australia. 30 November 2022. Retrieved 29 December 2022.

heartofengland.nhs.uk

repository.heartofengland.nhs.uk

Tam J, Nash EF, Ratjen F, Tullis E, Stephenson A (12 July 2013). "Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis" (PDF). The Cochrane Database of Systematic Reviews. 2013 (7): CD007168. doi:10.1002/14651858.CD007168.pub3. PMC 8078644. PMID 23852992. Archived from the original (PDF) on 27 March 2022. Retrieved 16 May 2018.

medicines.org.uk

"Acepiro 600 mg effervescent tablets - Summary of Product Characteristics (SmPC)". (emc). 30 August 2022. Retrieved 29 December 2022.

medscape.com

emedicine.medscape.com

Ataxia with Identified Genetic and Biochemical Defects at eMedicine
"Hemorrhagic Cystitis Treatment & Management: Approach Considerations, Clot Evacuation, Bladder Irrigation Agents". 5 December 2019. Retrieved 18 December 2019.

naturalproductsinsider.com

Long J (6 May 2021). "Amazon confirms plans on removing NAC supplements". Retrieved 21 September 2023.
Long J (22 April 2021). "Amazon reportedly removes NAC-containing dietary supplements". Natural Products Inside.
Long J (25 August 2022). "Amazon resumes sales of NAC supplements". Natural Products Insider. Retrieved 11 January 2023.

nih.gov

pubmed.ncbi.nlm.nih.gov

Sadowska AM, Verbraecken J, Darquennes K, De Backer WA (December 2006). "Role of N-acetylcysteine in the management of COPD". International Journal of Chronic Obstructive Pulmonary Disease. 1 (4): 425–434. doi:10.2147/copd.2006.1.4.425. ISSN 1176-9106. PMC 2707813. PMID 18044098.
Bin P, Huang R, Zhou X (2017). "Oxidation Resistance of the Sulfur Amino Acids: Methionine and Cysteine". BioMed Research International. 2017: 9584932. doi:10.1155/2017/9584932. PMC 5763110. PMID 29445748.
Lee BC, Dikiy A, Kim HY, Gladyshev VN (2009). "Functions and evolution of selenoprotein methionine sulfoxide reductases". Biochimica et Biophysica Acta (BBA) - General Subjects. 1790 (11): 1471–1477. doi:10.1016/j.bbagen.2009.04.014. PMC 3062201. PMID 19406207.
Green JL, Heard KJ, Reynolds KM, Albert D (May 2013). "Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis". The Western Journal of Emergency Medicine. 14 (3): 218–226. doi:10.5811/westjem.2012.4.6885. PMC 3656701. PMID 23687539.
Borgström L, Kågedal B, Paulsen O (1986). "Pharmacokinetics of N-acetylcysteine in man". European Journal of Clinical Pharmacology. 31 (2): 217–222. doi:10.1007/bf00606662. PMID 3803419. S2CID 41004554.
Dilger RN, Baker DH (July 2007). "Oral N-acetyl-L-cysteine is a safe and effective precursor of cysteine". Journal of Animal Science. 85 (7): 1712–1718. doi:10.2527/jas.2006-835. PMID 17371789.
Kanter MZ (October 2006). "Comparison of oral and i.v. acetylcysteine in the treatment of acetaminophen poisoning". American Journal of Health-System Pharmacy. 63 (19): 1821–1827. doi:10.2146/ajhp060050. PMID 16990628. S2CID 9209528.
Dawson AH, Henry DA, McEwen J (March 1989). "Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning". The Medical Journal of Australia. 150 (6): 329–331. doi:10.5694/j.1326-5377.1989.tb136496.x. PMID 2716644. S2CID 40296724.
Bailey B, McGuigan MA (June 1998). "Management of anaphylactoid reactions to intravenous N-acetylcysteine". Annals of Emergency Medicine. 31 (6): 710–715. doi:10.1016/S0196-0644(98)70229-X. PMID 9624310.
Schmidt LE, Dalhoff K (January 2001). "Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning". British Journal of Clinical Pharmacology. 51 (1): 87–91. doi:10.1046/j.1365-2125.2001.01305.x. PMC 2014432. PMID 11167669.
Lynch RM, Robertson R (January 2004). "Anaphylactoid reactions to intravenous N-acetylcysteine: a prospective case controlled study". Accident and Emergency Nursing. 12 (1): 10–15. doi:10.1016/j.aaen.2003.07.001. PMID 14700565.
Tam J, Nash EF, Ratjen F, Tullis E, Stephenson A (12 July 2013). "Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis" (PDF). The Cochrane Database of Systematic Reviews. 2013 (7): CD007168. doi:10.1002/14651858.CD007168.pub3. PMC 8078644. PMID 23852992. Archived from the original (PDF) on 27 March 2022. Retrieved 16 May 2018.
Grandjean EM, Berthet P, Ruffmann R, Leuenberger P (February 2000). "Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials". Clinical Therapeutics. 22 (2): 209–21. doi:10.1016/S0149-2918(00)88479-9. PMID 10743980.
Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR (August 2000). "The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review". The European Respiratory Journal. 16 (2): 253–262. doi:10.1034/j.1399-3003.2000.16b12.x. PMID 10968500.
Poole PJ, Black PN (May 2001). "Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review". BMJ. 322 (7297): 1271–1274. doi:10.1136/bmj.322.7297.1271. PMC 31920. PMID 11375228.
"Acetylcysteine", livertox.nih.gov, PMID 31643176, retrieved 26 April 2019
Buijtels PC, Petit PL (July 2005). "Comparison of NaOH–N-acetyl cysteine and sulfuric acid decontamination methods for recovery of mycobacteria from clinical specimens". Journal of Microbiological Methods. 62 (1): 83–88. doi:10.1016/j.mimet.2005.01.010. PMID 15823396.
Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, et al. (February 2010). "N-Acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus" (PDF). Biochemical Pharmacology. 79 (3): 413–420. doi:10.1016/j.bcp.2009.08.025. PMID 19732754.
Aslam S, Darouiche RO (September 2011). "Role of antibiofilm-antimicrobial agents in controlling device-related infections". The International Journal of Artificial Organs. 34 (9): 752–758. doi:10.5301/ijao.5000024. PMC 3251652. PMID 22094553.
Palmer LA, Doctor A, Chhabra P, Sheram ML, Laubach VE, Karlinsey MZ, et al. (September 2007). "S-Nitrosothiols signal hypoxia-mimetic vascular pathology". The Journal of Clinical Investigation. 117 (9): 2592–2601. doi:10.1172/JCI29444. PMC 1952618. PMID 17786245.
Hildebrandt W, Alexander S, Bärtsch P, Dröge W (March 2002). "Effect of N-acetyl-cysteine on the hypoxic ventilatory response and erythropoietin production: linkage between plasma thiol redox state and O₂ chemosensitivity". Blood. 99 (5): 1552–5. doi:10.1182/blood.V99.5.1552. PMID 11861267. S2CID 24375953.
Wang AL, Wang JP, Wang H, Chen YH, Zhao L, Wang LS, et al. (March 2006). "A dual effect of N-acetylcysteine on acute ethanol-induced liver damage in mice". Hepatology Research. 34 (3): 199–206. doi:10.1016/j.hepres.2005.12.005. PMID 16439183.
Steullet P, Neijt HC, Cuénod M, Do KQ (2006). "Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia". Neuroscience. 137 (3): 807–819. doi:10.1016/j.neuroscience.2005.10.014. ISSN 0306-4522. PMID 16330153. S2CID 1417873.
Varga V, Jenei Z, Janáky R, Saransaari P, Oja SS (1997). "Glutathione Is an Endogenous Ligand of Rat Brain N-Methyl-D-Aspartate (NMDA) and 2-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionate (AMPA) Receptors". Neurochemical Research. 22 (9): 1165–1171. doi:10.1023/A:1027377605054. ISSN 0364-3190. PMID 9251108. S2CID 24024090.
Oja SS (2000). "Modulation of glutamate receptor functions by glutathione". Neurochemistry International. 37 (2–3): 299–306. doi:10.1016/S0197-0186(00)00031-0. ISSN 0197-0186. PMID 10812215. S2CID 44380765.
Berk M, Malhi GS, Gray LJ, Dean OM (March 2013). "The promise of N-acetylcysteine in neuropsychiatry". Trends in Pharmacological Sciences. 34 (3): 167–177. doi:10.1016/j.tips.2013.01.001. PMID 23369637.
Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, et al. (August 2008). "Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients". Neuropsychopharmacology. 33 (9): 2187–2199. doi:10.1038/sj.npp.1301624. hdl:10536/DRO/DU:30071388. PMID 18004285.
Dodd S, Dean O, Copolov DL, Malhi GS, Berk M (December 2008). "N-Acetylcysteine for antioxidant therapy: pharmacology and clinical utility". Expert Opinion on Biological Therapy. 8 (12): 1955–1962. doi:10.1517/14728220802517901. PMID 18990082. S2CID 74736842.
Kupchik YM, Moussawi K, Tang XC, Wang X, Kalivas BC, Kolokithas R, et al. (June 2012). "The effect of N-acetylcysteine in the nucleus accumbens on neurotransmission and relapse to cocaine". Biological Psychiatry. 71 (11): 978–986. doi:10.1016/j.biopsych.2011.10.024. PMC 3340445. PMID 22137594.
Dean O, Giorlando F, Berk M (March 2011). "N-Acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action". Journal of Psychiatry & Neuroscience. 36 (2): 78–86. doi:10.1503/jpn.100057. PMC 3044191. PMID 21118657.
Head SI (29 October 2017). "Antioxidant therapy in a mouse model of Duchenne muscular dystrophy: some promising results but with a weighty caveat". The Journal of Physiology. 595 (23): 7015. doi:10.1113/jp275232. ISSN 0022-3751. PMC 5709324. PMID 29034480.
Gu F, Chauhan V, Chauhan A (January 2015). "Glutathione redox imbalance in brain disorders". Current Opinion in Clinical Nutrition and Metabolic Care. 18 (1): 89–95. doi:10.1097/MCO.0000000000000134. PMID 25405315. S2CID 25333289.
Bavarsad Shahripour R, Harrigan MR, Alexandrov AV (March 2014). "N-Acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities". Brain and Behavior. 4 (2): 108–122. doi:10.1002/brb3.208. PMC 3967529. PMID 24683506.
Bachert C, Hörmann K, Mösges R, Rasp G, Riechelmann H, Müller R, et al. (March 2003). "An update on the diagnosis and treatment of sinusitis and nasal polyposis". Allergy. 58 (3): 176–191. doi:10.1034/j.1398-9995.2003.02172.x. PMID 12653791. S2CID 35319457.
Aitio ML (January 2006). "N-Acetylcysteine – passe-partout or much ado about nothing?". British Journal of Clinical Pharmacology. 61 (1): 5–15. doi:10.1111/j.1365-2125.2005.02523.x. PMC 1884975. PMID 16390346.
Williamson J, Doig WM, Forrester JV, Tham MH, Wilson T, Whaley K, et al. (September 1974). "Management of the dry eye in Sjogren's syndrome". The British Journal of Ophthalmology. 58 (9): 798–805. doi:10.1136/bjo.58.9.798. PMC 1215027. PMID 4433493.
Lindblad AC, Rosenhall U, Olofsson A, Hagerman B (November–December 2011). "The efficacy of N-acetylcysteine to protect the human cochlea from subclinical hearing loss caused by impulse noise: a controlled trial". Noise & Health. 13 (55): 392–401. doi:10.4103/1463-1741.90293. PMID 22122955.
Edwards MJ, Hargreaves IP, Heales SJ, Jones SJ, Ramachandran V, Bhatia KP, et al. (November 2002). "N-acetylcysteine and Unverricht-Lundborg disease: variable response and possible side effects". Neurology. 59 (9): 1447–1449. doi:10.1212/wnl.59.9.1447. PMID 12427904.
McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM (2014). "Potential role of N-acetylcysteine in the management of substance use disorders". CNS Drugs. 28 (2): 95–106. doi:10.1007/s40263-014-0142-x. PMC 4009342. PMID 24442756.
Coppersmith V, Hudgins S, Stoltzfus J, Stankewicz H (June 2021). "The use of N-acetylcysteine in the prevention of hangover: a randomized trial". Scientific Reports. 11 (1): 13397. Bibcode:2021NatSR..1113397C. doi:10.1038/s41598-021-92676-0. PMC 8238992. PMID 34183702. S2CID 235673455.
De Flora S, Grassi C, Carati L (1 July 1997). "Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment". European Respiratory Journal. 10 (7): 1535–1541. doi:10.1183/09031936.97.10071535. PMID 9230243.
Ryu CM, Shin JH, Yu HY, Ju H, Kim S, Lim J, et al. (May 2019). "N-acetylcysteine prevents bladder tissue fibrosis in a lipopolysaccharide-induced cystitis rat model". Scientific Reports. 9 (1): 8134. Bibcode:2019NatSR...9.8134R. doi:10.1038/s41598-019-44631-3. PMC 6544636. PMID 31148586.
Pistolesi V, Regolisti G, Morabito S, Gandolfini I, Corrado S, Piotti G, et al. (December 2018). "Contrast medium induced acute kidney injury: a narrative review". Journal of Nephrology. 31 (6): 797–812. doi:10.1007/s40620-018-0498-y. PMID 29802583. S2CID 44128861.
Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, et al. (September 2021). "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research. 143: 230–238. doi:10.1016/j.jpsychires.2021.09.018. PMID 34509090. S2CID 237485915.
Carollo M, Carollo N, Montan G (February 2024). "The promise of N-acetylcysteine in the treatment of obsessive-compulsive disorder". CNS Neuroscience & Therapeutics. 30 (2): e14653. doi:10.1111/cns.14653. PMC 10883097. PMID 38385640.
Slattery J, Kumar N, Delhey L, Berk M, Dean O, Spielholz C, et al. (August 2015). "Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review". Neuroscience and Biobehavioral Reviews. 55: 294–321. doi:10.1016/j.neubiorev.2015.04.015. PMID 25957927.
Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, et al. (June 2014). "The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial". The Journal of Clinical Psychiatry. 75 (6): 628–636. doi:10.4088/JCP.13m08454. PMID 25004186.
Oliver G, Dean O, Camfield D, Blair-West S, Ng C, Berk M, et al. (April 2015). "N-Acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review". Clinical Psychopharmacology and Neuroscience. 13 (1): 12–24. doi:10.9758/cpn.2015.13.1.12. PMC 4423164. PMID 25912534.
Samuni Y, Goldstein S, Dean OM, Berk M (August 2013). "The chemistry and biological activities of N-acetylcysteine". Biochimica et Biophysica Acta (BBA) - General Subjects. 1830 (8): 4117–4129. doi:10.1016/j.bbagen.2013.04.016. hdl:11343/43874. PMID 23618697. S2CID 2567773.
Minarini A, Ferrari S, Galletti M, Giambalvo N, Perrone D, Rioli G, et al. (2 November 2016). "N-Acetylcysteine in the treatment of psychiatric disorders: current status and future prospects". Expert Opinion on Drug Metabolism & Toxicology. 13 (3): 279–292. doi:10.1080/17425255.2017.1251580. hdl:11380/1116466. PMID 27766914. S2CID 20873065.
Hwang AS, Campbell EH, Sartori-Valinotti JC (July 2022). "Evidence of N-acetylcysteine efficacy for skin picking disorder: A retrospective cohort study". Journal of the American Academy of Dermatology. 87 (1): 148–150. doi:10.1016/j.jaad.2021.06.874. PMID 34224772. S2CID 235746237.
Popova L, Mancuso J (2022). "Dramatic Improvement of Trichotillomania with 6 Months of Treatment With N-Acetylcysteine". Global Pediatric Health. 9: 2333794X221086576. doi:10.1177/2333794X221086576. PMC 9133858. PMID 35647220.
Nery FG, Li W, DelBello MP, Welge JA (November 2021). "N-acetylcysteine as an adjunctive treatment for bipolar depression: A systematic review and meta-analysis of randomized controlled trials". Bipolar Disorders. 23 (7): 707–714. doi:10.1111/bdi.13039. PMID 33354859. S2CID 229692736.
Wong KK, Lee SW, Kua KP (2021). "N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence". Journal of Inflammation Research. 14: 2993–3013. doi:10.2147/JIR.S306849. PMC 8274825. PMID 34262324.
Assimakopoulos SF, Aretha D, Komninos D, Dimitropoulou D, Lagadinou M, Leonidou L, et al. (2021). "N-Acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study". Infectious Diseases (London, England). 53 (11): 847–854. doi:10.1080/23744235.2021.1945675. PMID 34182881. S2CID 235673520.
Kapur A, Sharma M, Sageena G (2022). "Therapeutic potential of N-acetyl cysteine during COVID-19 epoch". World Journal of Virology. 11 (2): 104–106. doi:10.5501/wjv.v11.i2.104. PMC 8966593. PMID 35433335.
Kumar P, Osahon O, Vides DB, Hanania N, Minard CG, Sekhar RV (December 2021). "Severe Glutathione Deficiency, Oxidative Stress and Oxidant Damage in Adults Hospitalized with COVID-19: Implications for GlyNAC (Glycine and N-Acetylcysteine) Supplementation". Antioxidants. 11 (1): 50. doi:10.3390/antiox11010050. PMC 8773164. PMID 35052554.

ncbi.nlm.nih.gov

Sadowska AM, Verbraecken J, Darquennes K, De Backer WA (December 2006). "Role of N-acetylcysteine in the management of COPD". International Journal of Chronic Obstructive Pulmonary Disease. 1 (4): 425–434. doi:10.2147/copd.2006.1.4.425. ISSN 1176-9106. PMC 2707813. PMID 18044098.
Bin P, Huang R, Zhou X (2017). "Oxidation Resistance of the Sulfur Amino Acids: Methionine and Cysteine". BioMed Research International. 2017: 9584932. doi:10.1155/2017/9584932. PMC 5763110. PMID 29445748.
Lee BC, Dikiy A, Kim HY, Gladyshev VN (2009). "Functions and evolution of selenoprotein methionine sulfoxide reductases". Biochimica et Biophysica Acta (BBA) - General Subjects. 1790 (11): 1471–1477. doi:10.1016/j.bbagen.2009.04.014. PMC 3062201. PMID 19406207.
Green JL, Heard KJ, Reynolds KM, Albert D (May 2013). "Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis". The Western Journal of Emergency Medicine. 14 (3): 218–226. doi:10.5811/westjem.2012.4.6885. PMC 3656701. PMID 23687539.
Schmidt LE, Dalhoff K (January 2001). "Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning". British Journal of Clinical Pharmacology. 51 (1): 87–91. doi:10.1046/j.1365-2125.2001.01305.x. PMC 2014432. PMID 11167669.
Tam J, Nash EF, Ratjen F, Tullis E, Stephenson A (12 July 2013). "Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis" (PDF). The Cochrane Database of Systematic Reviews. 2013 (7): CD007168. doi:10.1002/14651858.CD007168.pub3. PMC 8078644. PMID 23852992. Archived from the original (PDF) on 27 March 2022. Retrieved 16 May 2018.
Poole PJ, Black PN (May 2001). "Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review". BMJ. 322 (7297): 1271–1274. doi:10.1136/bmj.322.7297.1271. PMC 31920. PMID 11375228.
Aslam S, Darouiche RO (September 2011). "Role of antibiofilm-antimicrobial agents in controlling device-related infections". The International Journal of Artificial Organs. 34 (9): 752–758. doi:10.5301/ijao.5000024. PMC 3251652. PMID 22094553.
Palmer LA, Doctor A, Chhabra P, Sheram ML, Laubach VE, Karlinsey MZ, et al. (September 2007). "S-Nitrosothiols signal hypoxia-mimetic vascular pathology". The Journal of Clinical Investigation. 117 (9): 2592–2601. doi:10.1172/JCI29444. PMC 1952618. PMID 17786245.
Kupchik YM, Moussawi K, Tang XC, Wang X, Kalivas BC, Kolokithas R, et al. (June 2012). "The effect of N-acetylcysteine in the nucleus accumbens on neurotransmission and relapse to cocaine". Biological Psychiatry. 71 (11): 978–986. doi:10.1016/j.biopsych.2011.10.024. PMC 3340445. PMID 22137594.
Dean O, Giorlando F, Berk M (March 2011). "N-Acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action". Journal of Psychiatry & Neuroscience. 36 (2): 78–86. doi:10.1503/jpn.100057. PMC 3044191. PMID 21118657.
Head SI (29 October 2017). "Antioxidant therapy in a mouse model of Duchenne muscular dystrophy: some promising results but with a weighty caveat". The Journal of Physiology. 595 (23): 7015. doi:10.1113/jp275232. ISSN 0022-3751. PMC 5709324. PMID 29034480.
Bavarsad Shahripour R, Harrigan MR, Alexandrov AV (March 2014). "N-Acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities". Brain and Behavior. 4 (2): 108–122. doi:10.1002/brb3.208. PMC 3967529. PMID 24683506.
Aitio ML (January 2006). "N-Acetylcysteine – passe-partout or much ado about nothing?". British Journal of Clinical Pharmacology. 61 (1): 5–15. doi:10.1111/j.1365-2125.2005.02523.x. PMC 1884975. PMID 16390346.
Williamson J, Doig WM, Forrester JV, Tham MH, Wilson T, Whaley K, et al. (September 1974). "Management of the dry eye in Sjogren's syndrome". The British Journal of Ophthalmology. 58 (9): 798–805. doi:10.1136/bjo.58.9.798. PMC 1215027. PMID 4433493.
McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM (2014). "Potential role of N-acetylcysteine in the management of substance use disorders". CNS Drugs. 28 (2): 95–106. doi:10.1007/s40263-014-0142-x. PMC 4009342. PMID 24442756.
Coppersmith V, Hudgins S, Stoltzfus J, Stankewicz H (June 2021). "The use of N-acetylcysteine in the prevention of hangover: a randomized trial". Scientific Reports. 11 (1): 13397. Bibcode:2021NatSR..1113397C. doi:10.1038/s41598-021-92676-0. PMC 8238992. PMID 34183702. S2CID 235673455.
Ryu CM, Shin JH, Yu HY, Ju H, Kim S, Lim J, et al. (May 2019). "N-acetylcysteine prevents bladder tissue fibrosis in a lipopolysaccharide-induced cystitis rat model". Scientific Reports. 9 (1): 8134. Bibcode:2019NatSR...9.8134R. doi:10.1038/s41598-019-44631-3. PMC 6544636. PMID 31148586.
Carollo M, Carollo N, Montan G (February 2024). "The promise of N-acetylcysteine in the treatment of obsessive-compulsive disorder". CNS Neuroscience & Therapeutics. 30 (2): e14653. doi:10.1111/cns.14653. PMC 10883097. PMID 38385640.
Oliver G, Dean O, Camfield D, Blair-West S, Ng C, Berk M, et al. (April 2015). "N-Acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review". Clinical Psychopharmacology and Neuroscience. 13 (1): 12–24. doi:10.9758/cpn.2015.13.1.12. PMC 4423164. PMID 25912534.
Popova L, Mancuso J (2022). "Dramatic Improvement of Trichotillomania with 6 Months of Treatment With N-Acetylcysteine". Global Pediatric Health. 9: 2333794X221086576. doi:10.1177/2333794X221086576. PMC 9133858. PMID 35647220.
Wong KK, Lee SW, Kua KP (2021). "N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence". Journal of Inflammation Research. 14: 2993–3013. doi:10.2147/JIR.S306849. PMC 8274825. PMID 34262324.
Kapur A, Sharma M, Sageena G (2022). "Therapeutic potential of N-acetyl cysteine during COVID-19 epoch". World Journal of Virology. 11 (2): 104–106. doi:10.5501/wjv.v11.i2.104. PMC 8966593. PMID 35433335.
Kumar P, Osahon O, Vides DB, Hanania N, Minard CG, Sekhar RV (December 2021). "Severe Glutathione Deficiency, Oxidative Stress and Oxidant Damage in Adults Hospitalized with COVID-19: Implications for GlyNAC (Glycine and N-Acetylcysteine) Supplementation". Antioxidants. 11 (1): 50. doi:10.3390/antiox11010050. PMC 8773164. PMID 35052554.

dailymed.nlm.nih.gov

"Acetadote- acetylcysteine injection, solution". DailyMed. 1 October 2021. Retrieved 29 December 2022.
"Mucomyst Package Insert". Archived from the original on 21 April 2014. Retrieved 20 April 2014.

pubchem.ncbi.nlm.nih.gov

"L-Cysteine, N-acetyl- — Compound Summary". PubChem. National Center for Biotechnology Information, U.S. National Library of Medicine. 25 March 2005. Identification. Archived from the original on 12 January 2014. Retrieved 9 January 2012.
"N-Acetyl-L-cysteine | C₅H₉NO₃S". PubChem. National Center for Biotechnology Information, U.S. National Library of Medicine. Archived from the original on 16 August 2016. Retrieved 22 July 2016.

livertox.nih.gov

"Acetylcysteine", livertox.nih.gov, PMID 31643176, retrieved 26 April 2019

patents.google.com

US3091569A, Leonard, Sheffner Aaron, "Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus", issued 28 May 1963

semanticscholar.org

api.semanticscholar.org

Borgström L, Kågedal B, Paulsen O (1986). "Pharmacokinetics of N-acetylcysteine in man". European Journal of Clinical Pharmacology. 31 (2): 217–222. doi:10.1007/bf00606662. PMID 3803419. S2CID 41004554.
Kanter MZ (October 2006). "Comparison of oral and i.v. acetylcysteine in the treatment of acetaminophen poisoning". American Journal of Health-System Pharmacy. 63 (19): 1821–1827. doi:10.2146/ajhp060050. PMID 16990628. S2CID 9209528.
Dawson AH, Henry DA, McEwen J (March 1989). "Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning". The Medical Journal of Australia. 150 (6): 329–331. doi:10.5694/j.1326-5377.1989.tb136496.x. PMID 2716644. S2CID 40296724.
Garrett CE, Prasad K (2004). "The Art of Meeting Palladium Specifications in Active Pharmaceutical Ingredients Produced by Pd-Catalyzed Reactions". Advanced Synthesis & Catalysis. 346 (8): 889–900. doi:10.1002/adsc.200404071. S2CID 94929244.
Hildebrandt W, Alexander S, Bärtsch P, Dröge W (March 2002). "Effect of N-acetyl-cysteine on the hypoxic ventilatory response and erythropoietin production: linkage between plasma thiol redox state and O₂ chemosensitivity". Blood. 99 (5): 1552–5. doi:10.1182/blood.V99.5.1552. PMID 11861267. S2CID 24375953.
Steullet P, Neijt HC, Cuénod M, Do KQ (2006). "Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia". Neuroscience. 137 (3): 807–819. doi:10.1016/j.neuroscience.2005.10.014. ISSN 0306-4522. PMID 16330153. S2CID 1417873.
Varga V, Jenei Z, Janáky R, Saransaari P, Oja SS (1997). "Glutathione Is an Endogenous Ligand of Rat Brain N-Methyl-D-Aspartate (NMDA) and 2-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionate (AMPA) Receptors". Neurochemical Research. 22 (9): 1165–1171. doi:10.1023/A:1027377605054. ISSN 0364-3190. PMID 9251108. S2CID 24024090.
Oja SS (2000). "Modulation of glutamate receptor functions by glutathione". Neurochemistry International. 37 (2–3): 299–306. doi:10.1016/S0197-0186(00)00031-0. ISSN 0197-0186. PMID 10812215. S2CID 44380765.
Dodd S, Dean O, Copolov DL, Malhi GS, Berk M (December 2008). "N-Acetylcysteine for antioxidant therapy: pharmacology and clinical utility". Expert Opinion on Biological Therapy. 8 (12): 1955–1962. doi:10.1517/14728220802517901. PMID 18990082. S2CID 74736842.
Gu F, Chauhan V, Chauhan A (January 2015). "Glutathione redox imbalance in brain disorders". Current Opinion in Clinical Nutrition and Metabolic Care. 18 (1): 89–95. doi:10.1097/MCO.0000000000000134. PMID 25405315. S2CID 25333289.
Bachert C, Hörmann K, Mösges R, Rasp G, Riechelmann H, Müller R, et al. (March 2003). "An update on the diagnosis and treatment of sinusitis and nasal polyposis". Allergy. 58 (3): 176–191. doi:10.1034/j.1398-9995.2003.02172.x. PMID 12653791. S2CID 35319457.
Coppersmith V, Hudgins S, Stoltzfus J, Stankewicz H (June 2021). "The use of N-acetylcysteine in the prevention of hangover: a randomized trial". Scientific Reports. 11 (1): 13397. Bibcode:2021NatSR..1113397C. doi:10.1038/s41598-021-92676-0. PMC 8238992. PMID 34183702. S2CID 235673455.
Pistolesi V, Regolisti G, Morabito S, Gandolfini I, Corrado S, Piotti G, et al. (December 2018). "Contrast medium induced acute kidney injury: a narrative review". Journal of Nephrology. 31 (6): 797–812. doi:10.1007/s40620-018-0498-y. PMID 29802583. S2CID 44128861.
Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, et al. (September 2021). "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research. 143: 230–238. doi:10.1016/j.jpsychires.2021.09.018. PMID 34509090. S2CID 237485915.
Samuni Y, Goldstein S, Dean OM, Berk M (August 2013). "The chemistry and biological activities of N-acetylcysteine". Biochimica et Biophysica Acta (BBA) - General Subjects. 1830 (8): 4117–4129. doi:10.1016/j.bbagen.2013.04.016. hdl:11343/43874. PMID 23618697. S2CID 2567773.
Minarini A, Ferrari S, Galletti M, Giambalvo N, Perrone D, Rioli G, et al. (2 November 2016). "N-Acetylcysteine in the treatment of psychiatric disorders: current status and future prospects". Expert Opinion on Drug Metabolism & Toxicology. 13 (3): 279–292. doi:10.1080/17425255.2017.1251580. hdl:11380/1116466. PMID 27766914. S2CID 20873065.
Hwang AS, Campbell EH, Sartori-Valinotti JC (July 2022). "Evidence of N-acetylcysteine efficacy for skin picking disorder: A retrospective cohort study". Journal of the American Academy of Dermatology. 87 (1): 148–150. doi:10.1016/j.jaad.2021.06.874. PMID 34224772. S2CID 235746237.
Nery FG, Li W, DelBello MP, Welge JA (November 2021). "N-acetylcysteine as an adjunctive treatment for bipolar depression: A systematic review and meta-analysis of randomized controlled trials". Bipolar Disorders. 23 (7): 707–714. doi:10.1111/bdi.13039. PMID 33354859. S2CID 229692736.
Assimakopoulos SF, Aretha D, Komninos D, Dimitropoulou D, Lagadinou M, Leonidou L, et al. (2021). "N-Acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study". Infectious Diseases (London, England). 53 (11): 847–854. doi:10.1080/23744235.2021.1945675. PMID 34182881. S2CID 235673520.

sigmaaldrich.com

"N-Acetyl-L-cysteine Product Information" (PDF). Sigma. Sigma-Aldrich. Archived from the original (PDF) on 11 June 2014. Retrieved 9 November 2014.

tga.gov.au

ebs.tga.gov.au

DBL ACETYLCYSTEINE injection concentrate acetylcysteine 2 g/ 10 mL injection ampoule
"TGA eBS - Product and Consumer Medicine Information Licence".
"Product Information: Aceradote® Concentrated Injection" (PDF). TGA eBusiness Services. Phebra Pty Ltd. 16 January 2013. Archived from the original on 8 September 2017. Retrieved 8 November 2013.

umm.edu

"Cysteine". University of Maryland Medical Center. Archived from the original on 1 July 2017. Retrieved 23 June 2017.

web.archive.org

Stockley RA (2008). Chronic Obstructive Pulmonary Disease a Practical Guide to Management. Chichester: John Wiley & Sons. p. 750. ISBN 9780470755280. Archived from the original on 8 September 2017.
"Acetylcysteine". The American Society of Health-System Pharmacists. Archived from the original on 23 September 2015. Retrieved 22 August 2015.
"L-Cysteine, N-acetyl- — Compound Summary". PubChem. National Center for Biotechnology Information, U.S. National Library of Medicine. 25 March 2005. Identification. Archived from the original on 12 January 2014. Retrieved 9 January 2012.
"N-Acetyl-L-cysteine Product Information" (PDF). Sigma. Sigma-Aldrich. Archived from the original (PDF) on 11 June 2014. Retrieved 9 November 2014.
Talbott SM (2012). A Guide to Understanding Dietary Supplements. Routledge. p. 469. ISBN 9781136805707. Archived from the original on 8 September 2017.
"Cysteine". University of Maryland Medical Center. Archived from the original on 1 July 2017. Retrieved 23 June 2017.
Fischer J, Ganellin CR (2006). Analogue-Based Drug Discovery. Weinheim: Wiley-VCH. p. 544. ISBN 9783527607495. Archived from the original on 8 September 2017.
Baker E (2014). "Acetylcysteine". Top 100 Drugs: Clinical pharmacology and practical prescribing. Elsevier Health Sciences. ISBN 9780702055157. Archived from the original on 8 September 2017.
"Acetadote Package Insert" (PDF). FDA. Archived (PDF) from the original on 25 August 2013. Retrieved 19 April 2014.
Tam J, Nash EF, Ratjen F, Tullis E, Stephenson A (12 July 2013). "Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis" (PDF). The Cochrane Database of Systematic Reviews. 2013 (7): CD007168. doi:10.1002/14651858.CD007168.pub3. PMC 8078644. PMID 23852992. Archived from the original (PDF) on 27 March 2022. Retrieved 16 May 2018.
"Mucomyst Package Insert". Archived from the original on 21 April 2014. Retrieved 20 April 2014.
"Product Information: Aceradote® Concentrated Injection" (PDF). TGA eBusiness Services. Phebra Pty Ltd. 16 January 2013. Archived from the original on 8 September 2017. Retrieved 8 November 2013.
"N-Acetyl-L-cysteine | C₅H₉NO₃S". PubChem. National Center for Biotechnology Information, U.S. National Library of Medicine. Archived from the original on 16 August 2016. Retrieved 22 July 2016.

worldcat.org

Sadowska AM, Verbraecken J, Darquennes K, De Backer WA (December 2006). "Role of N-acetylcysteine in the management of COPD". International Journal of Chronic Obstructive Pulmonary Disease. 1 (4): 425–434. doi:10.2147/copd.2006.1.4.425. ISSN 1176-9106. PMC 2707813. PMID 18044098.
Steullet P, Neijt HC, Cuénod M, Do KQ (2006). "Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia". Neuroscience. 137 (3): 807–819. doi:10.1016/j.neuroscience.2005.10.014. ISSN 0306-4522. PMID 16330153. S2CID 1417873.
Varga V, Jenei Z, Janáky R, Saransaari P, Oja SS (1997). "Glutathione Is an Endogenous Ligand of Rat Brain N-Methyl-D-Aspartate (NMDA) and 2-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionate (AMPA) Receptors". Neurochemical Research. 22 (9): 1165–1171. doi:10.1023/A:1027377605054. ISSN 0364-3190. PMID 9251108. S2CID 24024090.
Oja SS (2000). "Modulation of glutamate receptor functions by glutathione". Neurochemistry International. 37 (2–3): 299–306. doi:10.1016/S0197-0186(00)00031-0. ISSN 0197-0186. PMID 10812215. S2CID 44380765.
Head SI (29 October 2017). "Antioxidant therapy in a mouse model of Duchenne muscular dystrophy: some promising results but with a weighty caveat". The Journal of Physiology. 595 (23): 7015. doi:10.1113/jp275232. ISSN 0022-3751. PMC 5709324. PMID 29034480.